Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -17.46% is in line with its 5-year average of -18.67%, near the high end of its 5-year range (-45.28%–-7.17%).
45.91% above its 12-month average of -32.28%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.02%.
RETURN ON ASSETS (ROA)
-17.46%
RETURN ON ASSETS (ROA) AVG TTM
-32.28%
RETURN ON ASSETS (ROA) AVG 3Y
-24.08%
RETURN ON ASSETS (ROA) AVG 5Y
-18.67%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+45.91%
CURRENT VS 3Y AVG
+27.50%
CURRENT VS 5Y AVG
+6.46%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+45.84%
vs the sector median at left
908 Devices Inc.
Market Cap
$510.56M
Return on Assets (ROA)
-17.46%
TTM Avg
-32.28%
3Y Avg
-24.08%
5Y Avg
-18.67%
Market Cap
$509.10M
Return on Assets (ROA)
-30.08%
TTM Avg
-46.42%
3Y Avg
-46.30%
5Y Avg
-37.15%
Market Cap
$520.72M
Return on Assets (ROA)
-17.40%
TTM Avg
-49.85%
3Y Avg
-45.66%
5Y Avg
-41.17%
Market Cap
$499.62M
Return on Assets (ROA)
8.89%
TTM Avg
6.33%
3Y Avg
3.95%
5Y Avg
1.76%
Market Cap
$521.64M
Return on Assets (ROA)
-42.15%
TTM Avg
-50.20%
3Y Avg
-44.84%
5Y Avg
-47.93%
Market Cap
$521.97M
Return on Assets (ROA)
-89.18%
TTM Avg
-100.15%
3Y Avg
-92.96%
5Y Avg
-79.13%
Market Cap
$524.04M
Return on Assets (ROA)
-37.16%
TTM Avg
-32.95%
3Y Avg
-32.95%
5Y Avg
-32.95%
Market Cap
$524.16M
Return on Assets (ROA)
-16.69%
TTM Avg
-61.13%
3Y Avg
-63.72%
5Y Avg
-100.27%
Market Cap
$494.52M
Return on Assets (ROA)
-32.24%
TTM Avg
-55.64%
3Y Avg
-73.34%
5Y Avg
-69.35%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 908 Devices Inc. (MASS) | $510.56M | -17.46% | -32.28% | -24.08% | -18.67% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $509.10M | -30.08% | -46.42% | -46.30% | -37.15% |
| Altimmune, Inc. (ALT)vs › | $520.72M | -17.40% | -49.85% | -45.66% | -41.17% |
| Tactile Systems Technology, Inc. (TCMD)vs › | $499.62M | 8.89% | 6.33% | 3.95% | 1.76% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $521.64M | -42.15% | -50.20% | -44.84% | -47.93% |
| Crescent Biopharma, Inc. (CBIO)vs › | $521.97M | -89.18% | -100.15% | -92.96% | -79.13% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $524.04M | -37.16% | -32.95% | -32.95% | -32.95% |
| Immix Biopharma, Inc. (IMMX)vs › | $524.16M | -16.69% | -61.13% | -63.72% | -100.27% |
| Oculis Holding AG (OCS)vs › | $494.52M | -32.24% | -55.64% | -73.34% | -69.35% |
| Puma Biotechnology, Inc. (PBYI)vs › | $489.40M | 13.86% | 14.29% | 9.48% | 0.09% |
ROA
-17.5%
ROE
-27.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -19.28% |
| 2024-12-31 | -45.28% |
| 2023-12-31 | -17.93% |
| 2022-12-31 | -13.84% |
| 2021-12-31 | -8.50% |
| 2020-12-31 | -7.17% |
| 2019-12-31 | -35.51% |
| 2018-12-31 | -27.16% |
